

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

26 April 2023

Revised Timetable for Non-Renounceable Rights Issue to Raise \$2.1M

Zoono Group Limited (**Company**) (ASX: ZNO) advises that the indicative timetable as reflected in the prospectus as lodged with ASX earlier today for the Company's Rights Issue has been amended and revised. Following unexpected administrative delays associated with lodgement of the Prospectus and following consultation with the ASX, the Company has pushed out the Ex-date and the Record Date for determining Entitlements for the Rights Issue by one business day to 1 May and 2 May 2023 respectively and the Offer opening date, Prospectus sent out to Shareholders and Company announces this has been completed by one day to 5 May 2023.

There are no further changes to the timetable.

Revised Indicative Timetable

The revised timetable for the Rights Issue is set out below:

Lodgement of Prospectus with the ASIC	26 April 2023
Lodgement of Prospectus and Appendix 3B with ASX	26 April 2023
Ex date	1 May 2023
Record Date for determining Entitlements	2 May 2023
Offer opening date, Prospectus sent out to Shareholders and Company announces this has been completed	5 May 2023
Last day to extend the Closing Date	23 May 2023
Closing Date as at 5:00pm*	26 May 2023
Shares quoted on a deferred settlement basis	29 May 2023
ASX notified of under subscriptions	2 June 2023
Issue date and lodgement of Appendix 2A with ASX applying for quotation of the Shares	2 June 2023
Quotation of Shares issued under the Offer**	5 June 2023

*The Directors may extend the Closing Date by giving at least three (3) Business Days' notice to ASX prior to the Closing Date. Accordingly, the date the Securities are expected to commence trading on ASX may vary.

This announcement has been authorised and approved for release to ASX by the CEO of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

Group MD

M: +64 21 659 977

E: paul.hyslop@zoono.com

Paul Ravlich

Group CFO

M: +64 21 075 9176

E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'ZOONO molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the Company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com